

France's Sanofi buys biotech company Ablynx for \$4.8 billion

January 29 2018

French drugmaker Sanofi has made another big purchase aimed at strengthening its position in rare disease treatments, buying Belgian biotech company Ablynx for 3.9 billion euros (\$4.8 billion).

Sanofi announced Monday that the deal was approved by the boards of both companies. Sanofi is paying 45 euros per share.

Danish drugmaker Novo Nordisk had also sought to buy Ablynx but the Belgian company said Novo Nordisk's offers were too low.

Ablynx is notably developing nanobodies, small antibodies that it hopes can be used to treat [blood disorders](#), inflammation and [respiratory diseases](#).

Sanofi says the purchase will boost its rare blood disorder portfolio, after announcing earlier this month that it's buying U.S. hemophilia specialist Bioverativ for \$11.6 billion.

The [pharmaceutical industry](#) is seeing increasing interest in rare diseases.

© 2018 The Associated Press. All rights reserved.

Citation: France's Sanofi buys biotech company Ablynx for \$4.8 billion (2018, January 29)
retrieved 26 April 2024 from
<https://medicalxpress.com/news/2018-01-france-sanofi-biotech-company-ablynx.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.